Current Pharmaceutical DesignCurrent Pharmaceutical DesignCurrent Pharmaceutical Design1381-61281873-4286Bentham Science64575310.2174/0113816128289465240422074745Immunology, Inflammation & AllergyResearch ArticleWhich Drugs are More Effective in Preventing Familial Adenomatous Polyposis Progression based on Network Meta-analysis?LuoPeiinfo@benthamscience.netShiWenjuninfo@benthamscience.netChengXianshuoinfo@benthamscience.netYangJuninfo@benthamscience.netPeiGeninfo@benthamscience.netDongJianinfo@benthamscience.netColorectal Surgery Department, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical UniversityColorectal Surgery Departmen, The First Affiliated Hospital of Kunming Medical University3005202430201548156311012025Copyright ©; 2024, Bentham Science Publishers2024Bentham Science Publishershttps://journals.eco-vector.com/1381-6128/article/view/645753

Background:Familial adenomatous polyposis (FAP) is an inherited disorder. At present, an increasing number of medications are being employed to treat FAP; however, only a few have been assessed for their efficacy and safety. Therefore, this study aimed to conduct a network meta-analysis to compare the therapeutic outcomes and adverse drug reactions of all FAP-associated medications.

Methods:Six relevant databases were searched to identify pertinent randomized controlled trials (RCTs), and information on the dosage and frequency of various drugs was extracted. Additionally, data on changes in polyp counts and dimensions, as well as treatment-related adverse reactions for different medications were collected. The Bayesian method was employed to directly or indirectly compare the impact of different treatment regimens on changes in polyp numbers and diameters, and the safety of the drugs was investigated.

Results:CXB at 16 mg/kg/day significantly reduced polyp numbers. Celecoxib at 8 mg/kg/day and sulindac (150 mg twice daily) plus erlotinib (75 mg/day) were effective for tolerant FAP patients. Additionally, EPAFFA 2 g daily and sulindac (150 mg twice daily) plus erlotinib (75 mg/day) emerged as the most effective for reducing polyp size.

Conclusion:The most effective treatment for reducing the number of colorectal polyps is celecoxib 16 mg/kg/day. On the other hand, a daily dosage of 2 g EPA-FFA demonstrates the best results in terms of decreasing colorectal polyp diameter.

Familial adenomatous polyposisdrug treatmentinherited disordernetwork meta-analysispolyp countsBayesian method.Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis 2009; 4(1): 22. doi: 10.1186/1750-1172-4-22 PMID: 19822006Dinarvand P, Davaro EP, Doan JV, et al. Familial adenomatous polyposis syndrome: An update and review of extraintestinal manifestations. Arch Pathol Lab Med 2019; 143(11): 1382-98. doi: 10.5858/arpa.2018-0570-RA PMID: 31070935Laurent S, Franchimont D, Coppens JP, et al. Familial adenomatous polyposis: Clinical presentation, detection and surveillance. Acta Gastroenterol Belg 2011; 74(3): 415-20. PMID: 22103047Dolan S. Familial adenomatous polyposis: Development, presentation, and treatment strategies. Clin J Oncol Nurs 2019; 23(2): 135-8. doi: 10.1188/19.CJON.135-138 PMID: 30880794Aihara H, Kumar N, Thompson CC. Diagnosis, surveillance, and treatment strategies for familial adenomatous polyposis. Eur J Gastroenterol Hepatol 2014; 26(3): 255-62. doi: 10.1097/MEG.0000000000000010 PMID: 24161962Stanich PP, Sullivan B, Kim AC, Kalady MF. Endoscopic management and surgical considerations for familial adenomatous polyposis. Gastrointest Endosc Clin N Am 2022; 32(1): 113-30. doi: 10.1016/j.giec.2021.08.007 PMID: 34798980Vitellaro M, Ferrari A, Trencheva K, et al. Is laparoscopic surgery an option to support prophylactic colectomy in adolescent patients with Familial Adenomatous Polyposis (FAP)? Pediatr Blood Cancer 2012; 59(7): 1223-8. doi: 10.1002/pbc.24113 PMID: 22378577Kemp Bohan PM, Mankaney G, Vreeland TJ, et al. Chemoprevention in familial adenomatous polyposis: past, present and future. Fam Cancer 2021; 20(1): 23-33. doi: 10.1007/s10689-020-00189-y PMID: 32507936Vasen HFA, Möslein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008; 57(5): 704-13. doi: 10.1136/gut.2007.136127 PMID: 18194984Lynch PM. Low-dose aspirin and mesalazine for patients with familial adenomatous polyposis. Lancet Gastroenterol Hepatol 2021; 6(6): 418-9. doi: 10.1016/S2468-1253(21)00102-3 PMID: 33812493Herendeen JM, Lindley C. Use of NSAIDs for the chemoprevention of colorectal cancer. Ann Pharmacother 2003; 37(11): 1664-74. doi: 10.1345/aph.1C489 PMID: 14565811Roser C, Tóth C, Renner M, Herpel E, Schirmacher P. Expression of apoptosis repressor with caspase recruitment domain (ARC) in familial adenomatous polyposis (FAP) adenomas and its correlation with DNA mismatch repair proteins, p53, Bcl-2, COX-2 and beta-catenin. Cell Commun Signal 2021; 19(1): 15. doi: 10.1186/s12964-020-00702-x PMID: 33579312Shi YJ, Zhao QQ, Liu XS, et al. Toll‐like receptor 4 regulates spontaneous intestinal tumorigenesis by up‐regulating IL‐6 and GM‐CSF. J Cell Mol Med 2020; 24(1): 385-97. doi: 10.1111/jcmm.14742 PMID: 31650683Xavier A, Scott RJ, Talseth-Palmer B. Exome sequencing of familial adenomatous polyposis‐like individuals identifies both known and novel causative genes. Clin Genet 2021; 100(4): 478-83. doi: 10.1111/cge.14029 PMID: 34259353Paziewska A, Horbacka K, Goryca K, et al. Transcriptional changes between uninflamed ulcerative colitis and familial adenomatous polyposis pouch mucosa can be attributed to an altered immune response. Acta Biochim Pol 2015; 62(1): 69-75. doi: 10.18388/abp.2014_778 PMID: 25654358Khan N, Lipsa A, Arunachal G, Ramadwar M, Sarin R. Novel mutations and phenotypic associations identified through APC, MUTYH, NTHL1, POLD1, POLE gene analysis in Indian Familial Adenomatous Polyposis cohort. Sci Rep 2017; 7(1): 2214. doi: 10.1038/s41598-017-02319-6 PMID: 28533537Keane S, Herring M, Rolny P, Wettergren Y, Ejeskär K. Inflammation suppresses DLG2 expression decreasing inflammasome formation. J Cancer Res Clin Oncol 2022; 148(9): 2295-311. doi: 10.1007/s00432-022-04029-7 PMID: 35499706Shureiqi I. Molecular predicators of duodenal familial adenomatous polyposis chemoprevention: do chemopreventive drugs hit their presumed molecular targets? Cancer Prev Res 2018; 11(1): 1-3. doi: 10.1158/1940-6207.CAPR-17-0372 PMID: 29263155Benamouzig R, Uzzan B, Little J, Chaussade S. Low dose aspirin, COX-inhibition and chemoprevention of colorectal cancer. Curr Top Med Chem 2005; 5(5): 493-503. doi: 10.2174/1568026054201631 PMID: 15974944Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann Intern Med 2015; 162(11): 777-84. doi: 10.7326/M14-2385 PMID: 26030634Burke CA, Dekker E, Lynch P, et al. Eflornithine plus sulindac for prevention of progression in familial adenomatous polyposis. N Engl J Med 2020; 383(11): 1028-39. doi: 10.1056/NEJMoa1916063 PMID: 32905675Park JJ, Kim BC, Hong SP, et al. The effect of metformin in treatment of adenomas in patients with familial adenomatous polyposis. Cancer Prev Res 2021; 14(5): 563-72. doi: 10.1158/1940-6207.CAPR-20-0580 PMID: 33509804Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, Sugihara K. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 2003; 9(13): 4756-60. PMID: 14581346Burke C, Phillips R, Berger MF, et al. Children’s International Polyposis (CHIP) study: A randomized, double-blind, placebo-controlled study of celecoxib in children with familial adenomatous polyposis. Clin Exp Gastroenterol 2017; 10: 177-85. doi: 10.2147/CEG.S121841 PMID: 28765715Burn J, Bishop DT, Chapman PD, et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res 2011; 4(5): 655-65. doi: 10.1158/1940-6207.CAPR-11-0106 PMID: 21543343Balaguer F, Stoffel EM, Burke CA, et al. Combination of sulindac and eflornithine delays the need for lower gastrointestinal surgery in patients with familial adenomatous polyposis: Post hoc analysis of a randomized clinical trial. Dis Colon Rectum 2022; 65(4): 536-45. doi: 10.1097/DCR.0000000000002095 PMID: 34261858Cruz-Correa M, Hylind LM, Marrero JH, et al. Efficacy and safety of curcumin in treatment of intestinal adenomas in patients with familial adenomatous polyposis. Gastroenterology 2018; 155(3): 668-73. doi: 10.1053/j.gastro.2018.05.031 PMID: 29802852Debinski HS, Trojan J, Nugent KP, Spigelman AD, Phillips RKS. Effect of sulindac on small polyps in familial adenomatous polyposis. Lancet 1995; 345(8953): 855-6. doi: 10.1016/S0140-6736(95)92989-4 PMID: 7898240Delker DA, Wood AC, Snow AK, et al. Chemoprevention with cyclooxygenase and epidermal growth factor receptor inhibitors in familial adenomatous polyposis patients: mrna signatures of duodenal neoplasia. Cancer Prev Res 2018; 11(1): 4-15. doi: 10.1158/1940-6207.CAPR-17-0130 PMID: 29109117Gilad O, Rosner G, Ivancovsky-Wajcman D, et al. Efficacy of wholistic turmeric supplement on adenomatous polyps in patients with familial adenomatous polyposis a randomized, double-blinded, placebo-controlled study. Genes 2022; 13(12): 2182. doi: 10.3390/genes13122182 PMID: 36553450Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328(18): 1313-6. doi: 10.1056/NEJM199305063281805 PMID: 8385741Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002; 346(14): 1054-9. doi: 10.1056/NEJMoa012015 PMID: 11932472Ishikawa H, Wakabayashi K, Suzuki S, et al. Preventive effects of low‐dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: Double‐blind, randomized clinical trial. Cancer Med 2013; 2(1): 50-6. doi: 10.1002/cam4.46 PMID: 24133627Iwama T, Akasu T, Utsunomiya J, Muto T. Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial. Int J Clin Oncol 2006; 11(2): 133-9. doi: 10.1007/s10147-005-0548-z PMID: 16622748Keller JJ, Offerhaus GJA, Polak M, et al. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac. Gut 1999; 45(6): 822-8. doi: 10.1136/gut.45.6.822 PMID: 10562579Ladenheim J, Garcia G, Titzer D, et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology 1995; 108(4): 1083-7. doi: 10.1016/0016-5085(95)90206-6 PMID: 7698575Lynch PM, Ayers GD, Hawk E, et al. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol 2010; 105(6): 1437-43. doi: 10.1038/ajg.2009.758 PMID: 20234350Lynch PM, Burke CA, Phillips R, et al. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut 2016; 65(2): 286-95. doi: 10.1136/gutjnl-2014-307235 PMID: 25792707Nugent KP, Farmer KCR, Spigelman AD, Williams CB, Phillips RKS. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 2005; 80(12): 1618-9. doi: 10.1002/bjs.1800801244 PMID: 8298943Pasricha PJ, Bedi A, O’Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995; 109(3): 994-8. doi: 10.1016/0016-5085(95)90411-5 PMID: 7657130Phillips RKS, Wallace MH, Lynch PM, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002; 50(6): 857-60. doi: 10.1136/gut.50.6.857 PMID: 12010890Samadder NJ, Neklason DW, Boucher KM, et al. Effect of sulindac and erlotinib vs. placebo on duodenal neoplasia in familial adenomatous polyposis: A randomized clinical trial. JAMA 2016; 315(12): 1266-75. doi: 10.1001/jama.2016.2522Sinicrope FA, Half E, Morris JS, et al. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 2004; 13(6): 920-7. doi: 10.1158/1055-9965.920.13.6Ura H, Togi S, Hatanaka H, Niida Y. Establishment of a human induced pluripotent stem cell line, KMUGMCi004-A, from a patient bearing a heterozygous c.1832delG mutation in the APC gene leading familial adenomatous polyposis (FAP). Stem Cell Res 2022; 63: 102867. doi: 10.1016/j.scr.2022.102867 PMID: 35868288Chiang JM, Chen HW, Tang RP, et al. Mutation analysis of the APC gene in Taiwanese FAP families: low incidence of APC germline mutation in a distinct subgroup of FAP families. Fam Cancer 2010; 9(2): 117-24. doi: 10.1007/s10689-009-9292-2 PMID: 19768578Yen T, Stanich PP, Axell L, Patel SG. Apc-Associated Polyposis Conditions. Apc-Associated Polyposis Conditions. In: Adam MP, Mirzaa GM, Pagon RA, et al, Eds. Genereviews(®). Seattle (WA): University of Washington, Seattle Copyright© 1993-2023, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved 1993.Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol 2006; 101(2): 385-98. doi: 10.1111/j.1572-0241.2006.00375.x PMID: 16454848Sheng JQ, Li SR, Yang XY, et al. Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis. Zhonghua Yi Xue Za Zhi 2006; 86(8): 526-9. PMID: 16681880Davis JS, Kanikarla-Marie P, Gagea M, et al. Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development. BMC Cancer 2020; 20(1): 871. doi: 10.1186/s12885-020-07311-4 PMID: 32912193Giardiello FM. NSAID-induced polyp regression in familial adenomatous polyposis patients. Gastroenterol Clin North Am 1996; 25(2): 349-61. doi: 10.1016/S0889-8553(05)70251-X PMID: 9229577Davies NM, Gudde TW, de Leeuw MAWC. Celecoxib: A new option in the treatment of arthropathies and familial adenomatous polyposis. Expert Opin Pharmacother 2001; 2(1): 139-52. doi: 10.1517/14656566.2.1.139 PMID: 11336575Brophy JM. Celecoxib and cardiovascular risks. Expert Opin Drug Saf 2005; 4(6): 1005-15. doi: 10.1517/14740338.4.6.1005 PMID: 16255660Bannwarth B. COX-2 selective drugs and cardiovascular risks: Same data but discrepant conclusions? Expert Opin Drug Saf 2006; 5(1): 1-2. doi: 10.1517/14740338.5.1.1 PMID: 16370948van Heumen BWH, Roelofs HMJ, Vink-Börger M, et al. Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: A multicentre, randomized controlled trial. Orphanet J Rare Dis 2013; 8(1): 118. doi: 10.1186/1750-1172-8-118 PMID: 23919274Seow-Choen F, Vijayan V, Keng V. Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polyps in familial adenomatous polyposis. Br J Surg 2005; 83(12): 1763-6. doi: 10.1002/bjs.1800831232 PMID: 9038563Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355(9): 873-84. doi: 10.1056/NEJMoa061355 PMID: 16943400